FDA CRL - Rocket Pharmaceuticals, Inc.

On June 14, 2024, Rocket Pharmaceuticals, Inc. received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning their Biologics License Application (BLA) for marnetegragene autotemcel. Final approval was withheld due to significant deficiencies, primarily within the Chemistry, Manufacturing, and Controls (CMC) section of the application. The main issue identified was the company's failure to formally update the BLA documents with numerous revisions and corrections that had been confirmed during the interactive review process. These unaddressed updates included typographical and calculation errors in standard operating procedures and validation reports, as well as agreed-upon changes to specifications, acceptance criteria, and validated assay ranges. The FDA also noted that comments on the proposed labeling are reserved until the other deficiencies are resolved. Under the regulatory framework of 21 CFR 601.3(b), Rocket Pharmaceuticals is required to fully address all identified deficiencies. This entails formally incorporating all corrected and revised information into the BLA submission, providing red-lined versions of all modified documents, and submitting a tabulated summary detailing every change made. The company must resubmit the application or withdraw it within one year of the letter's date, or request an extension, as a partial response will not initiate a new review cycle. A meeting or teleconference with the FDA is an available option to discuss the necessary steps for approval.